Medical cannabis histories: Charlotte’s Web, Cannatonic and Bedrocan

What do these three medical cannabis histories explain?

Charlotte’s Web, Cannatonic and Bedrocan illuminate different parts of medical cannabis history: patient experience, cultivar development and product standardization. A cultivar name alone does not establish a treatment benefit. Individual accounts, batch records and clinical trials answer different questions. This article follows the documents behind all three cases and explains what each kind of evidence can support. Maa & Figi · Epilepsia (2014) Resin Seeds · lineage correction (2015) Dutch Office of Medicinal Cannabis

Three documents, three different questions

Put three documents beside one another: a report about a child with severe seizures, a breeder’s correction to a cultivar history, and a release certificate from the Dutch medicinal-cannabis system. Each belongs in the history of medical cannabis. Each answers a different question: what happened to one person, where a plant was said to come from, and what was checked in a particular batch. The interesting story begins when we resist treating those answers as interchangeable.

This is a history of Charlotte’s Web, Cannatonic and Bedrocan, rather than a ranking of flowers for particular diagnoses. It follows families, breeders, regulators and researchers. Their achievements are worth understanding precisely because the evidence changes along the way. A moving story can identify an urgent question; a reproducible product can make that question testable. Neither automatically supplies the final clinical answer.

Charlotte: before the brand, a child and her family

Edward Maa and Paige Figi’s 2014 Epilepsia report described Charlotte, a child with Dravet syndrome, receiving a CBD-rich extract alongside existing antiseizure medication. The authors reported a substantial reduction in convulsive seizures during follow-up. Paige was Charlotte’s mother and a coauthor. This was a patient case with a family’s perspective inside it, not a blinded comparison establishing how every child would respond. Maa & Figi · Epilepsia (2014)

According to the company’s timeline, Paige met Joel Stanley, one of the Colorado-based Stanley brothers, in February 2012 and the family obtained their CBD-rich, low-THC preparation. Charlotte’s experience became associated with the plant name Charlotte’s Web, subsequently also a brand name. Sanjay Gupta’s CNN documentary brought wider attention in August 2013. These retrospective details come from the company involved, rather than an independent reconstruction. Charlotte’s Web · company timeline (2022)

Listen to experience without making one patient prove everything

Maa’s 2014 medical presentation discussed Charlotte’s case, parent surveys and the development of a defined CBD research product separately. It captures an important clinical situation: families were already making decisions while questions about composition, accompanying medicines and risk required better studies. The slides are useful historical evidence of that conversation, not a substitute for current prescribing information. Edward Maa · medical presentation (2014)

A case can reveal a question that deserves investigation. Explaining a change still requires examining concurrent treatment, variation in the condition and how outcomes were counted. Keeping those questions open does not diminish a family’s experience. It prevents that experience from being turned into a promise to someone whose diagnosis, medicines and circumstances may be very different.

Cannatonic: a discovery outside the original target

Resin Seeds describes work with Reggae Seeds in the late 2000s and the identification of a roughly balanced CBD–THC Cannatonic phenotype at Spannabis in 2008. Its account says the initial interest was in THC plants with a Diesel-like aroma. As a breeder’s recollection, this is a compelling story of noticing an unexpected characteristic. It does not establish that the company discovered CBD itself or began all medical-cannabis breeding. Resin Seeds · breeder history and FAQ

In 2015 the company corrected its published lineage from MK-Ultra × G13 to Reina Madre × NYCD. That small archival turn is valuable: even the original supplier’s account can change. The notice establishes a correction to the breeder’s description. It does not present independent DNA verification. A responsible cultivar history keeps both the correction and the kind of evidence visible. Resin Seeds · lineage correction (2015)

One name does not promise one chemical profile

Resin Seeds’ Cannatonic description gives a THC:CBD range from 30:1 to 1:30. This is a supplier statement, not an independent survey of the market, but it clearly does not promise one fixed ratio for everything bearing the name. Distinguishing genotype, phenotype and chemotype helps identify whether a claim concerns a label, inherited variation, an observed characteristic or a measured chemical profile. Resin Seeds · Cannatonic technical description

A breeder’s narrative helps frame questions of provenance; a matching laboratory report addresses composition in the tested material. If the two do not align, keep the document dates, versions and unresolved questions. Do not erase the inconvenient document to produce a tidier family tree. For readers and manufacturers alike, an honest correction can be more informative than an immaculate story with no traceable records.

Bedrocan: making quality reproducible

Bedrocan traces its business to Tjalling Erkelens and Freerk Bruining in 1984, initially growing vegetables and herbs under controlled conditions. Its account describes standardized cannabis work in the 1990s and supply to the Dutch programme in 2003. This is company history, but the story extends beyond a producer’s expertise to a public system with records readers can inspect. Bedrocan · company history

The Dutch Office of Medicinal Cannabis dates its responsibilities to 1 January 2001, covering medicinal and scientific cannabis and supply to pharmacies and research. Its role links production, oversight and intended destinations. A functioning supply system is consequential, but it is a different achievement from establishing that every supplied product is effective for every condition. Dutch Office of Medicinal Cannabis

Following a name to an actual batch

Bedrocan is both a company name and the name of one product. The Dutch office’s list checked on 11 October 2026 distinguishes Bedrocan, approximately 22% THC and below 1% CBD, from Bedrolite, below 1% THC and approximately 7.5% CBD. Similar branding does not make them interchangeable CBD-rich products. These are descriptive specifications, not instructions for selecting treatment. OMC · medicinal cannabis products

The Bedrolite release certificate for batch 25L15FR26A14, dated 26 February 2026, identifies parties, batch information, dates, methods and quality or contaminant checks. Unlike a free-floating “medical grade” claim, it supplies a specific document to examine. It remains a quality record, not an efficacy trial. Reading a COA starts with the sample and the scope of testing. OMC · Bedrolite batch 25L15FR26A14 (2026)

What a controlled trial adds

The 2017 NEJM trial randomized 120 participants aged 2–18 with drug-resistant Dravet syndrome to CBD oral solution or placebo alongside existing treatment. Over 14 treatment weeks, median monthly convulsive seizures changed from 12.4 to 5.9 with CBD and from 14.9 to 14.1 with placebo. Adverse events were more frequent with CBD; GW Pharmaceuticals funded the study. These findings concern the defined trial product and population, not every CBD preparation. Devinsky et al. · Dravet trial, NEJM (2017)

A comparison group helps distinguish change during treatment from change under the comparison conditions. The question becomes more specific than whether someone improved. Duration also bounds the answer: findings over a study period do not supply lifetime outcomes. A group median does not predict one individual’s response. These distinctions are part of understanding the result, not reasons to ignore it.

Standardization can produce complicated answers

A 2019 Pain crossover study compared Bedrocan products with placebo in 20 people with fibromyalgia after one vapor inhalation and three hours of observation. Overall spontaneous and electrical pain responses were not superior to placebo. However, THC-containing products increased pressure-pain thresholds, and more Bediol recipients reached at least a 30% pain-score reduction at one or more measurements. An author was affiliated with Bedrocan. Outcomes, brief follow-up and affiliations belong beside the findings. van de Donk et al. · Pain (2019)

This is an often overlooked value of standardization: it makes a product more precisely describable and studyable, even when the answer is not uniformly positive. For an evidence-focused industry, success cannot mean collecting only flattering outcomes. It also means identifying what can be reproduced, what was measured and which questions remain unanswered.

An approved CBD medicine still requires clinical care

The FDA distinguishes evaluated medicines such as Epidiolex from general cannabis or CBD products. Approval belongs to a product and its indications, not automatically to every plant sharing an ingredient. Likewise, Charlotte’s story preceding an approval does not prove that one event directly caused the regulatory decision. US FDA · cannabis-derived medicines

The May 2026 Epidiolex label covers seizures associated with Dravet syndrome, Lennox–Gastaut syndrome and tuberous sclerosis complex in patients aged at least one year. It also addresses hepatic injury, somnolence, diarrhoea and interactions involving medicines such as valproate and clobazam. CBD does not mean side-effect-free. A cultivar story is not a basis for stopping or changing prescribed treatment. DailyMed · EPIDIOLEX label, revised May 2026

Five questions that improve an evidence conversation

For Thai readers, Mahidol University’s science explainer provides an introduction to Thai cannabis and medical context. Its 2022 legal discussion must be separated from current rules. The same boundary applies across countries: a Dutch supply system or US medicine approval does not automatically establish Thai marketing or import authorization. มหาวิทยาลัยมหิดล · กัญชาพันธุ์ไทยและการแพทย์ (2022)

What these histories ask of Thailand’s industry

Charlotte’s history asks us to listen to patients. Cannatonic asks us to keep the corrections in the archive. The Dutch system shows the value of traceable material. For BUDS THAILAND, an ambition for high-quality Thai cannabis includes honest histories, room for disappointing findings and claims that do not borrow authority from a famous name. Good industry work should clarify patients’ questions, rather than make uncertain answers sound settled.

The medical-evidence chapter in our main documentary places these histories in a wider context. Our hemp and cannabis comparison explains why a plant category and a medicine authorization answer different questions. Sources were checked through 11 October 2026. This article explains evidence; it does not report a BUDS clinical trial or provide individualized treatment advice.